Hemab Therapeutics reports wider Q3 2026 loss as cash reserves dip

Hemab Therapeutics announced a third‑quarter 2026 net loss of $27.3 million, or $0.58 per share, versus a $17.1 million loss a year earlier. Research and development spending rose to $24.6 million and overhead costs increased, pushing total operating expenses higher. The company ended the quarter with $430.2 million in cash and marketable securities, which it says will fund operations through 2029. CEO Benny Sørensen highlighted the start of a Phase 3 trial for sutacimig and other pipeline milestones.

The larger loss and higher expense base may pressure the share price, as reflected by a 5‑6% pre‑market decline. The cash runway to 2029 gives the firm time to advance its clinical programs without immediate financing risk.

  • 1Quarterly net loss was $27.3 million, or $0.58 per share.
  • 2Loss in the comparable quarter a year earlier was $17.1 million.
  • 3Research and development expenses for the quarter totaled $24.6 million, up from $14.6 million a year earlier.
  • 4Overhead costs rose to $5.1 million, compared with $2.5 million in the prior-year quarter.
  • 5Cash, cash equivalents and marketable securities were $430.2 million as of September 30, 2026.
  • 6LifeSci Capital initiated coverage with an Outperform rating and a $65 price target.

Sources